{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:57:29Z","timestamp":1761058649205},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.jad.2007.02.004","type":"journal-article","created":{"date-parts":[[2007,3,27]],"date-time":"2007-03-27T11:16:30Z","timestamp":1174994190000},"page":"S15-S22","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S1","title":["Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder"],"prefix":"10.1016","volume":"100","author":[{"given":"Caleb M.","family":"Adler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Brecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Strakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4 Suppl","key":"10.1016\/j.jad.2007.02.004_bib1","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","author":"American Psychiatric Association","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2007.02.004_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2007.02.004_bib3","series-title":"Data on File","author":"AstraZeneca Pharmaceuticals LP","year":"2005"},{"key":"10.1016\/j.jad.2007.02.004_bib4","unstructured":"AstraZeneca Pharmaceuticals LP, 2005b. SEROQUEL\u00ae (quetiapine fumarate) tablets \u2014 Prescribing Information."},{"issue":"2\u20133","key":"10.1016\/j.jad.2007.02.004_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0920-9964(97)00131-X","article-title":"Factors influencing relapse in the long-term course of schizophrenia","volume":"28","author":"Ayuso-Gutierrez","year":"1997","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.jad.2007.02.004_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/713847170","article-title":"Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study","volume":"29","author":"Bobes","year":"2003","journal-title":"J. Sex Marital Ther."},{"issue":"1","key":"10.1016\/j.jad.2007.02.004_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v66n0116","article-title":"A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder","volume":"66","author":"Bowden","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2007.02.004_bib8","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1185\/030079904125004510","article-title":"Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials","volume":"20","author":"Buckley","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.jad.2007.02.004_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00023210-200418030-00004","article-title":"Quetiapine. A review of its use in the management of schizophrenia","volume":"18","author":"Cheer","year":"2004","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.jad.2007.02.004_bib10","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/00004583-200210000-00011","article-title":"A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania","volume":"41","author":"DelBello","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psych."},{"issue":"2","key":"10.1016\/j.jad.2007.02.004_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00406-004-0509-y","article-title":"Pharmacological long-term treatment strategies in first episode schizophrenia-study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia","volume":"254","author":"Gaebel","year":"2004","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"suppl 1","key":"10.1016\/j.jad.2007.02.004_bib12","first-page":"50","article-title":"Quetiapine for rapid-cycling bipolar disorder: a long-term follow-up study [abstract]","volume":"5","author":"Ghaemi","year":"2003","journal-title":"Bipolar Disord."},{"issue":"2","key":"10.1016\/j.jad.2007.02.004_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0269881103017002003","article-title":"Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology","volume":"17","author":"Goodwin","year":"2003","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jad.2007.02.004_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/15622970209150612","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression","volume":"3","author":"Grunze","year":"2002","journal-title":"World J. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2007.02.004_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/15622970309167904","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders, Part II: Treatment of mania","volume":"4","author":"Grunze","year":"2003","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2007.02.004_bib16","first-page":"S26","article-title":"Safety in treating bipolar disorder","author":"Gupta","year":"2003","journal-title":"J. Fam. Pract."},{"issue":"1","key":"10.1016\/j.jad.2007.02.004_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4088\/JCP.v64n0111","article-title":"Screening for bipolar disorder in the community","volume":"64","author":"Hirschfeld","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 5","key":"10.1016\/j.jad.2007.02.004_bib18","first-page":"43","article-title":"Tardive dyskinesia in affective disorders","volume":"60","author":"Kane","year":"1999","journal-title":"J. Clin. Psychiatry"},{"issue":"suppl 4","key":"10.1016\/j.jad.2007.02.004_bib19","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/S0924-977X(01)00109-2","article-title":"Extrapyramidal side effects are unacceptable","volume":"11","author":"Kane","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.jad.2007.02.004_bib21","first-page":"292","article-title":"Factors associated with pharmacologic noncompliance in patients with mania","volume":"57","author":"Keck","year":"1996","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2007.02.004_bib20","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania","volume":"160","author":"Keck","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2007.02.004_bib22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","article-title":"Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial","volume":"160","author":"Keck","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2007.02.004_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3956(03)00099-2","article-title":"Psychotic bipolar disorders: dimensionally similar to or categorically different from schizophrenia?","volume":"38","author":"Ketter","year":"2004","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2007.02.004_bib23","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jad.2007.02.006","article-title":"Rates of remission\/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania","volume":"100","author":"Ketter","year":"2007","journal-title":"J. Affect. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.jad.2007.02.004_bib25","first-page":"60","article-title":"Risperidone monotherapy in acute bipolar mania (abstract P108)","volume":"5","author":"Khanna","year":"2003","journal-title":"Bipolar Disord."},{"issue":"2","key":"10.1016\/j.jad.2007.02.004_bib26","article-title":"Schizophrenia and bipolar disorder: an evolving interface","volume":"9","author":"Korn","year":"2004","journal-title":"Medscape Psychiatr. Ment. Health"},{"key":"10.1016\/j.jad.2007.02.004_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0447.1994.tb05825.x","article-title":"Neuroleptics and the neuroleptic-induced deficit syndrome","volume":"380","author":"Lewander","year":"1994","journal-title":"Acta Psychiatr. Scand., Suppl."},{"issue":"11 Suppl 12","key":"10.1016\/j.jad.2007.02.004_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1017\/S1092852900028856","article-title":"Safety considerations in pharmacotherapy of bipolar disorder","volume":"9","author":"Masand","year":"2004","journal-title":"CNS Spectr."},{"issue":"5","key":"10.1016\/j.jad.2007.02.004_bib29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.euroneuro.2005.02.006","article-title":"Quetiapine or haloperidol as monotherapy for bipolar mania\u2014a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial","volume":"15","author":"McIntyre","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2007.02.004_bib30","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jad.2007.02.007","article-title":"Quetiapine in the treatment of acute bipolar mani: Efficacy aross a broad range of symptoms","volume":"100","author":"McIntyre","year":"2007","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.jad.2007.02.004_bib31","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1185\/030079904X2312","article-title":"A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone","volume":"20","author":"Mintzer","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2007.02.004_bib32","series-title":"154th Annual Meeting of the American Psychiatric Association, New Orleans, LA","article-title":"Reversal of weight gain associated with antipsychotic treatment","author":"O'Keefe","year":"2001"},{"issue":"7","key":"10.1016\/j.jad.2007.02.004_bib34","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":"Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety","volume":"159","author":"Sachs","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2007.02.004_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-5618.2004.00115.x","article-title":"Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study","volume":"6","author":"Sachs","year":"2004","journal-title":"Bipolar Disord."},{"issue":"2","key":"10.1016\/j.jad.2007.02.004_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0950-351X(95)80386-6","article-title":"Clinical impact of hyperprolactinaemia","volume":"9","author":"Schlechte","year":"1995","journal-title":"Bailliere's Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.jad.2007.02.004_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mp.4000336","article-title":"Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors","volume":"3","author":"Seeman","year":"1998","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2007.02.004_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002018-200022030-00004","article-title":"Tolerability of atypical antipsychotics","volume":"22","author":"Stanniland","year":"2000","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.jad.2007.02.004_bib39","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00023210-200115090-00004","article-title":"Comparative efficacy and tolerability of drug treatments for bipolar disorder","volume":"15","author":"Strakowski","year":"2001","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.jad.2007.02.004_bib38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1517\/14656566.4.5.751","article-title":"Atypical antipsychotics in the treatment of bipolar disorder","volume":"4","author":"Strakowski","year":"2003","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jad.2007.02.004_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00004850-200405000-00010","article-title":"Use of quetiapine in bipolar disorder: a case series with prospective evaluation","volume":"19","author":"Suppes","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.jad.2007.02.004_bib40","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4088\/JCP.v66n0710","article-title":"The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder","volume":"66","author":"Suppes","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"3 Suppl 1","key":"10.1016\/j.jad.2007.02.004_bib42","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/01.jcp.0000084037.22282.a3","article-title":"The implications of weight changes with antipsychotic treatment","volume":"23","author":"Sussman","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2007.02.004_bib43","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jad.2007.02.008","article-title":"Rates of remission\/euthymia with quetiapine in combination with lithium\/divalproex for the treatment of acute mania","volume":"100","author":"Sussman","year":"2007","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jad.2007.02.004_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10401230209149099","article-title":"Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome","volume":"14","author":"Tandon","year":"2002","journal-title":"Ann. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2007.02.004_bib46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group","volume":"156","author":"Tohen","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2007.02.004_bib45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group","volume":"57","author":"Tohen","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2007.02.004_bib48","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1185\/030079905X46340","article-title":"Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies","volume":"21","author":"Vieta","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2007.02.004_bib47","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jad.2007.02.009","article-title":"Quetiapine in the treatment of acute mania: Target dose for efficacious treatment","volume":"100","author":"Vieta","year":"2007","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2007.02.004_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00002018-200124010-00005","article-title":"Bodyweight gain with atypical antipsychotics. A comparative review","volume":"24","author":"Wetterling","year":"2001","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.jad.2007.02.004_bib50","first-page":"3","article-title":"Risk factors for tardive dyskinesia according to primary psychiatric diagnosis","volume":"9","author":"Wolf","year":"1987","journal-title":"Hillside J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2007.02.004_bib51","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.jcp.0000144887.66319.2f","article-title":"Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania","volume":"24","author":"Yatham","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"suppl 8","key":"10.1016\/j.jad.2007.02.004_bib52","first-page":"52","article-title":"Antipsychotic drug side effect issues in bipolar manic patients","volume":"61","author":"Zarate","year":"2000","journal-title":"J. Clin. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032707000766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032707000766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T05:34:49Z","timestamp":1683783289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032707000766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":52,"alternative-id":["S0165032707000766"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2007.02.004","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}